In May and June several oncology drugs have been newly approved or been designated a new indication by the FDA.
The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery.
In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant‒free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019).
Results of a randomized clinical trial, presented at ASCO 2018, highlight the benefit of preoperative chemoradiotherapy for patients with pancreatic cancer that can be treated with surgery.
The PRODIGE 7 randomized study has demonstrated that for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy delivered to the abdomen during surgery, may not be necessary.
Analysis of cancer registry data has revealed that women with head and neck cancer were less likely to receive intensive chemotherapy and radiation compared to men.
ASCO18: Prostate cancer survival in black men following chemotherapy may be as good, or better, as in white men
Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.
Advanced triple-negative breast cancer patients who have inherited a BRCA mutation are twice as likely to benefit from carboplatin as docetaxel, a novel study suggests.
A novel treatment strategy could overcome drug resistance in testicular cancer, find out exclusive details in this interview with study leader Janet Shipley from the ICR (London, UK).
Discover cases studies of rare recurrences after adjuvant chemotherapy in this Editorial from Future Oncology.